Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of tisagenlecleucel versus standard of care in relapsed or refractory follicular lymphoma
2023-503452-27-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Aug 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial in follicular lymphoma (FL) comparing Tisagenlecleucel arm with Standard of care arm (2 arms). Primary endpoint: Progression-free survival. Planned start Aug 2023; status: authorised.
02
Drugs
tisagenlecleucel
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2023-503452-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503452-27-00.